Bedrijfsoverzicht
Sensus Healthcare, Inc. is a medical device enterprise dedicated to the manufacture and distribution of radiation therapy devices for global healthcare providers. The firm leverages superficial radiation therapy, a specific low-energy X-ray technology, within its portfolio of treatment solutions, with the SRT-100 photon X-ray device serving as a key offering. Operating within the Healthcare sector and the Medical Devices industry, the company provides specialized equipment used for therapeutic radiation applications. In terms of scale, the organization reports a market capitalization of $73.91M and generates $27.48M in annual revenue while employing a workforce of 60 individuals. These financial figures indicate that Sensus Healthcare functions as a small-cap entity with a relatively modest revenue base compared to large-scale medical device conglomerates. The narrow employee-to-revenue ratio suggests a lean operational structure, yet the market cap reflects investor valuation that is not directly proportional to current revenue generation, highlighting a potential divergence between market expectations and current financial output. The company's position as a specialized niche player is evident in its focus on specific radiation therapy technologies rather than broad-spectrum medical equipment.
Financiële gezondheid
The company reported $27.48M in revenue for the trailing twelve months, yet posted a net income loss of $-7,719,000 and an EBITDA of $-9,921,000. The substantial gap between the positive revenue of $27.48M and the significant negative net income reveals a heavy cost structure where operating expenses heavily outweigh gross profits before interest and taxes. Despite the negative earnings, the entity maintains positive free cash flow of $3.94M, which provides a critical buffer for financial flexibility and allows the company to fund operations without immediate external financing. This positive cash flow generation stands in contrast to the accounting losses, suggesting that non-cash charges or timing differences in expense recognition are contributing to the reported net loss. The firm holds $22.08M in cash assets against a total debt load of only $471,000, resulting in a debt-to-equity ratio of 0.98. While the absolute debt level is minimal, the debt-to-equity metric of 0.98 indicates a moderate level of leverage relative to equity, though the overwhelming cash balance mitigates immediate solvency risks. The balance sheet appears conservative in terms of absolute debt, yet the high leverage ratio requires careful monitoring as the company seeks to improve profitability. Liquidity is exceptionally strong, evidenced by a current ratio of 9.72, which indicates the company possesses nearly ten times the current assets necessary to cover its short-term liabilities. Return on Equity stands at -14.9% and Return on Assets is -11.2%, metrics that reveal management has not yet generated positive returns on the capital invested by shareholders or asset holders. These negative return metrics underscore the ongoing challenges in converting revenue into net profit and utilizing assets efficiently to generate shareholder value.
Waarderingsbeoordeling
Valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive earnings over the trailing twelve months. The forward P/E ratio is significantly higher at 70.90, implying that the market prices in substantial expected earnings growth to justify the current stock price in the future. The price-to-book ratio is 2.87, indicating that the market values the company at a premium of nearly three times its net book value. This premium suggests investors are pricing in future intangible assets, technology value, or growth potential that is not reflected in the current accounting book value. The price-to-sales ratio stands at 2.69, while the EV/EBITDA ratio is -5.27, reflecting the company's negative earnings before interest, taxes, depreciation, and amortization. These alternative valuation metrics suggest the market is focusing on revenue multiples rather than earnings multiples, which is typical for pre-profitable or turnaround-stage companies. Regarding trading range, the 52-week high is $5.92 and the 52-week low is $3.03. Without a specific current price provided in the facts, the valuation is assessed strictly through these historical price bounds which define the volatility floor and ceiling for the stock. The beta value is 1.28, which indicates that the stock price is more volatile than the broader market, tending to amplify market movements with greater intensity.
Growth & Income
The revenue growth year-over-year is -62.2%, while the earnings growth year-over-year is N/A due to the absence of prior period earnings data for comparison. The negative revenue growth indicates a contraction in sales, and since earnings are also negative, there is no data to support the claim that earnings are growing faster than revenue. The company does not distribute dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests its available earnings, or in this case, its free cash flow, back into the business to support operations and potentially fund product development rather than returning capital to shareholders. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, relying instead on cash flow generation and asset liquidity to sustain operations. The lack of dividend payouts and the negative earnings growth highlight a focus on survival and operational restructuring rather than shareholder income distribution or top-line expansion during this period.